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Abstract
Streptococcus pneumoniae (Sp) strain TIGR4 is a virulent, encapsulated serotype that
causes bacteremia, otitis media, meningitis and pneumonia. Increased bacterial resistance
and limited efficacy of the available vaccine to some serotypes complicate the treatment of
diseases associated to this microorganism. Flavodoxins are bacterial proteins involved in
several important metabolic pathways. The Sp flavodoxin (Spfld) gene was recently
reported to be essential for the establishment of meningitis in a rat model, which makes
SpFld a potential drug target. To facilitate future pharmacological studies, we have cloned
and expressed SpFld in E. coli and we have performed an extensive structural and bio-
chemical characterization of both the apo form and its active complex with the FMN cofac-
tor. SpFld is a short-chain flavodoxin containing 146 residues. Unlike the well-
characterized long-chain apoflavodoxins, the Sp apoprotein displays a simple two-state
thermal unfolding equilibrium and binds FMN with moderate affinity. The X-ray structures of
the apo and holo forms of SpFld differ at the FMN binding site, where substantial rearrange-
ment of residues at the 91±100 loop occurs to permit cofactor binding. This work will set up
the basis for future studies aiming at discovering new potential drugs to treat S. pneumo-
niae diseases through the inhibition of SpFld.
Introduction
Streptococcus pneumoniae is a gram-positive bacterium that causes pneumonia, meningitis, oti-
tis media, acute sinusitis, septicemia, and conjunctivitis, among several other diseases [1–4].
TheWorld Health Organization (WHO) considers Streptococcus pneumoniae a major health
problem due to the elevated mortality of some of the diseases associated to this pathogen. It is
estimated that close to 500,000 children under 5 years died in 2008 as a consequence of
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pneumococcal infections [5]. More specifically, pneumococcalmeningitis causes death in
around 25% of cases, plus neurological diseases in half of the survivors [6]. The emerging resis-
tance of S. pneumoniae to established antibiotics [7], the fact that current polysaccharide-
related vaccines are only protective to certain infective serotypes, and the fluctuation of the
prevalence of some pneumococcal serotypes over time due to selection forces (i.e.: 7vPCV vac-
cine) or serotype replacement [8] advice for the identification of new S. pneumoniae targets,
common to the different serotypes, that could be used to develop novel antibiotics to specifi-
cally combat S. pneumoniae infections.
In a recent work [9], several Sp TIGR4 genes [10] were identified as essential for S. pneumo-
niae infection during experimentalmeningitis in rats. One of them is the gene encoding flavo-
doxin (Spfld), a protein that has been shown to be essential for several other bacteria (http://
tubic.tju.edu.cn/deg/) [11], including Escherichia coli [12, 13], Salmonella enterica [14],Hae-
mophilus influenzae [15], Vibrio cholerae [16], andHelicobacter pylori [17]. Flavodoxins are
electron transfer proteins that participate in a variety of reactions in prokaryotes and in some
unicellular algae [18]. In Azobacter vinelandii, Fld participates in the reduction of nitrate [19],
in E. coli it mediates the activation of different enzymes such as anaerobic ribonucleotide
reductase [20], cobalamin-dependentmethionine synthase [21], biotin synthase [22] and pyru-
vate formate-lyase [23]. In some organisms, such as S. pneumoniae, the importance of flavo-
doxin has been tentatively associated to its participation in methionine synthesis [9]. The
identification of flavodoxin as an essential protein for S. pneumoniae infectivity and the fact
that flavodoxin is not present in humans open the possibility of using it as a target for the
development of novel and specific antimicrobials against S. pneumoniae. Related to this poten-
tial use of flavodoxins as drug targets [24] the flavodoxin fromHelicobacter pylori (HpFld) has
been subjected to detailed functional [25], structural [26] and biophysical [27–30] analyses that
have facilitated the discovery of novel specific inhibitors with bactericidal properties [31, 32].
In contrast to this wealth of information onHpFld, very little is known of SpFld. According to
its gene sequence translation [9], it contains 147 residues and very likely belongs to the so-
called short-chain flavodoxins [18] characterized by the lack of a 20-residue loop that, in the
long-chain flavodoxins, appears intercalated in the fifth β-strand. Hence, SpFld shows a higher
sequence identity with other short-chain flavodoxins, such as Streptococcus pyrogenes (76%) or
Desulfovibrio desulfuricans (45,3%), than with long-chain flavodoxins, such as those fromHeli-
cobacter pylori (25,7%),Anabaena PCC7119 (22,4%) or Escherichia coli (25,7%). The more
detailed flavodoxinmolecular and structural studies have been devoted to a few long-chain fla-
vodoxins, especially those from Anabaena PCC7119 [33–35], Azobobacter vinelandii [36] and
Helicobacter pylori [17, 28]. The lack of information about SpFld can hardly be alleviated by
resourcing to the limited data available for other short-chain flavodoxins. In this work we pro-
vide a detailed biophysical characterization of SpFld and report the x-ray structures of the apo
and holo forms, the conformational stability of the protein and the thermodynamic characteri-
zation of the cofactor binding equilibrium. These studies provide the target characterization
needed to pursue the rational discovery of specific inhibitors against SpFld. In addition, they
will contribute to understand better the specific structural and thermodynamic characteristics
of short-chain flavodoxins.
Results and Discussion
Spectroscopic properties of the holo and apo SpFld forms
The UV-visible absorption spectrumof purified SpFld (Fig 1a) shows the typical hallmarks of
flavin binding proteins, with two sizable absorption peaks at 371 and 456 nm, a pronounced
shoulder at 480 nm, and no absorption beyond 550 nm, indicative of a completely oxidized
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Fig 1. S. pneumoniae flavodoxin absorption and fluorescence spectra. (a)UV/VIS absorbance of
39 μM holo (solid line) and 134 μM apoflavodoxin (dashed line) in 150mMNaCl, 100mMMES, pH 6.5. (b)
Spectra related to three redox states of 43 μM SpFld in 150mMNaCl, 100mMMES, pH 6.5 at 10ÊC:
Oxidized (solid line), semiquinone (dashed line) with absorption maxima at 592 nm and reduced (dotted line).
(c) Fluorescence emission spectra of 20 μM SpFld holoprotein (solid line) and 20 μM apoprotein (dashed
line), in 150mMNaCl, 100mMMES, pH 6.5, 10ÊC.
doi:10.1371/journal.pone.0161020.g001
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flavin cofactor. The very low 271 nm/456 nm absorbance ratio of 3.3 is consistent with the
absence of tryptophan residues and the presence of only five tyrosine residues in its sequence.
The UV-visible spectrumof apo SpFld shows a single peak with maximal absorbance at 277
nm (Fig 1a) and a completely flat spectrumbeyond 350 nm, indicative of both a full removal of
the cofactor and a lack of protein aggregation phenomena. The apoflavodoxinmolar extinction
coefficient at 277 nm in 150 mMNaCl, 100 mMMES, pH 6.5, determined as described [37],
was 7.2 mM-1cm-1. The extinction coefficient at 456 nm (λmax) of the fully oxidized holoprotein
in the same buffer, determined as described [38], was 9.1 mM-1cm-1. To observe SpFld reduced
species, a partial FMN reduction in pseudo-anaerobic conditions was done with sodiumdithio-
nite (Fig 1b). The stabilized semiquinone exhibits a maximum at 592 nm. The low accumula-
tion of semiquinone observed suggests (assuming a typical FMN semiquinone extinction
coefficient around 5.0 mM-1 cm-1 at that wavelength) that the Eox/sq redox potential could be
slightly more negative than the Esq/hq one. Most of the flavin signal (95% at λmax) is lost in the
reduced form. The fluorescence emission spectra of holo SpFld (Fig 1c) displays characteristic
peaks of tyrosine residues and of the FMN cofactor. On the other hand, the apoprotein shows a
single maximum of emission at 310 nm, as expected from its amino acid composition.
The far-UV CD spectra of the holo and apoproteins (Fig 2a) indicate that, in solution, the
secondary structure content of the apo form is lower than that of the holoprotein. In contrast,
in the crystal structures (see below) the two forms appear to display very similar secondary
structure contents. The near-UV CD spectra of apo SpFld (Fig 2b) is characterized by a single
negative peak at 280 nm that must arise from the tyrosine residues in the protein. The presence
of a peak in this spectral region, which is characteristic of well-folded proteins [39], indicates
that, in solution, at least one tyrosine residue is located in a structurally well-defined region.
On the other hand, the near-UV CD spectrumof holoprotein (Fig 2b and 2c) is more complex
and reveals several contributions of the FMN cofactor that also arise as a consequence of its
interaction with a well-structured protein moiety [40]. The FMN-protein interaction gives rise
to prominent peaks in the visible region at the wavelengths of maximal absorbance of the FMN
cofactor. The CD data together suggests that both the apo and holo forms display well defined
tertiary structures in solution, but suggests that the apo form overall secondary structure con-
tent may be lower than that observed in the crystal structure (see below). The near-UV CD
spectra and the fluorescence emission spectra of apo SpFld are different from those of Ana-
baena andHp flavodoxins, which are dominated by positive peaks in the near-UV CD and by
longer fluorescence emission wavelengths characteristic of tryptophan containing proteins.
SpFld thus displays a specific spectroscopic identity that allows it to be distinguished from the
aforementioned long-chain flavodoxins based on simple fluorescence and CD spectra.
SpFld thermal stability
The stability of holo and apo SpFld has been determined from thermal unfolding curves. The
far UV-CD and near-UV CD thermal unfolding curves of the apo SpFld, roughly normalized
to signal spans from approximately 0 to 1, are shown in Fig 3a. Their fair superposition sug-
gests that the apoprotein follows a two-state thermal unfoldingmechanism. The individual fits
of the two curves to two-state equations (eqs 1 and 2) give similar temperatures of mid dena-
turation (around 30°C) and similar enthalpy changes (around 50 kcal mol-1). Their global anal-
ysis confirms the two-state model and provides a Tm of 30.8 ± 2°C and an enthalpy change of
41 ± 5 kcal mol-1 (Table 1).
The thermal unfolding of holo SpFld was monitored by far-UV CD, near-UV CD and FMN
fluorescence. The unfolding curves, roughly normalized to signal spans from zero to one (Fig
3b), can also be superimposed, suggesting a simple two-state unfolding equilibrium for the
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Fig 2. CD spectra of holo and apo SpFld in 150mMNaCl, 100mMMES, pH 6.5, 4ÊC.(a) Far-CD spectra
of 80 μM of holo and apo SpFld (continuous and dashed lines respectively) (b) Near-CD spectra of 80 μM of
holo (continuous line) and apo (dashed line) SpFld. (c) Visible-CD spectrum of 80 μM of holoprotein.
doi:10.1371/journal.pone.0161020.g002
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Fig 3. Thermal unfolding curvesmonitored spectroscopically in 150mMNaCl, 100mMMES pH 6.5.
(a) (80 μM) holoSpFld by Fluorescence (open triangles, gray line), far-UV CD (black circles, black line) and
near-UVCD (open squares, gray line). (b) (80 μM) apo SpFld by far-UV CD (black circles, black line) and
near-UVCD (open squares, gray line).
doi:10.1371/journal.pone.0161020.g003
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holoprotein [41]. Their individual fitting to a two-state equation provide Tm values around
44.5°C and enthalpy changes around 50 kcal mol-1. The global analysis of the three curves gave
rise to a Tm of 44.6 ± 0.2°C and an enthalpy change of 51±1 kcal mol
-1 (Table 1), similar to the
values obtained in the individual fits. The fact that the Tm of the holoflavodoxin is higher than
that of the apoprotein is the expected behavior for any protein whose native conformation
binds a ligand, in this case the FMN cofactor, as it has been discussed before in the context of
the apoflavodoxin/FMNequilibrium in other species [28, 30, 42].
The thermal unfolding of the holo and apo SpFld has also been investigated by DSC (Fig 4).
Analysis of the thermograms of either form of the protein confirms that the unfolding equilib-
rium is two-state with only one cooperative transition. The calorimetricTm and ΔH values are
similar to those derived from the spectroscopic analysis (Table 1) and confirm that the holo-
protein is more stable than the apoprotein.
Although little is known about the stability of short-chain flavodoxins, the stability of long-
chain ones has been studied in detail [18], specially usingAnabaena PCC 7119 flavodoxin, as a
model. In long-chain flavodoxins, the thermal unfolding of the apoform is at least three-state
(four-state inH. pylori [28]) because a partly unfolded intermediate conformation accumulates
as the temperature is raised before the protein becomes fully unfolded. The structure of this
major thermal intermediate has been determined at atomic resolution [43]. Roughly, two-
thirds of it displays a native conformation while the other third, encompassing the long loop of
long-chain flavodoxins and neighboring residues, is unfolded. In addition, protein engineering
experiments have shown that removal of the long loop gives rise to a shortened well-folded
Anabaena apoflavodoxin, which behaves as two-state towards thermal unfolding [44]. There-
fore, it is well established that the equilibrium thermal intermediate of long-chain flavodoxins
is associated to the autonomous unfolding of the long loop. Our spectroscopic and calorimetric
analysis of the short-chain Sp apoflavodoxin thermal unfolding indicates that no thermal inter-
mediate accumulates, which suggests that short-chain apoflavodoxins may generally follow a
simple two-state equilibrium unfoldingmechanism.
Unlike in previous studies in our group on the stability of other flavodoxins, we have used
here a slightly acidic buffer and a higher ionic strength because, otherwise, the conformational
stability of Sp apoflavodoxin is significantly lower, and it is difficult to determine accurately. In
fact, at the conditions typically used to characterizeAnabaena orHp apoflavodoxins (i.e. pH 7
and around 20 mM ionic strength), Sp apoflavodoxin appears to be unfolded (not shown). This
lower stability is unlikely related to the absence of a long loop in the short-chain SpFld. Our
previous analysis of the influence of the Anabaena PCC 7119 long loop in the conformational
stability of that long-chain flavodoxin [44] showed that removal of the long loop hardly modi-
fied the conformational stability of the protein. The low stability of SpFld in low ionic strength
Table 1. Thermal stability parameters for holo and apo SpFld.
Holo Flavodoxina Apo Flavodoxina
Far-UV
CD
Near-UV
CD
Fluoresc. Global ®tb DSC Far-UV
CD
Near-UV
CD
Global ®tb DSC
Tm 44.7±0.4 43.7±1 44.5±0.3 44.6±0.2 46.7±0.5 30.3±0.1 30.4±0.8 30.8±2 34.2±0.5
(ÊC)
ΔHm 52±2 38±3 65.8±0.1 51±1 61±2 51±1 50.5±0.6 41±5 55±2
(kcal mol-1)
a In 150 mM NaCl, 100 mMMES, pH 6.5.
b Parameters obtained through global analysis of the spectroscopic curves using a two-state unfolding model.
doi:10.1371/journal.pone.0161020.t001
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conditions is more likely related to its peculiar amino acid composition. In fact, the progres-
sively decreasing conformational stability of theH. pylori, Anabaena PCC 7119 and Sp apofla-
vodoxins at neutral pH and low ionic strength correlates with their increasing relative content
of acidic residues (27/164, 31/169 and 38/148, respectively) that gives rise to an increasingly
large excess of negative charge at pH 7 (approximately -12, -17 and -28, respectively). This
interpretation is in agreement with the fact that, in the Anabaena protein, more stable variants
have been engineered by reducing the net negative charge of the apoprotein [45, 46].
SpFld interaction with FMN
The higher thermostability of Sp holoflavodoxin compared to that of the apo form is a conse-
quence of the favorable interactions established between the apoprotein and the cofactor. To
quantitate this effect, the interaction between the apoprotein and the FMN cofactor was studied
by isothermal titration calorimetry at 15, 20 and 25°C (Fig 5 and Table 2). In addition, buffer-
independent binding parameters were determined by using buffers with different ionization
Fig 4. DSC analysis in the absence of FMN (open squares) or in the presence of 40 μMof FMN (open circles) in 150mMNaCl, 100mMMES, pH
6.5. The continuous line is the non-linear fitting curve obtained by using a two-state model for the unfolding of apoFld.
doi:10.1371/journal.pone.0161020.g004
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Fig 5. Titration of 20 μMApo SpFld with 300 μMFMN at 25ÊCin 150mMNaCl, 100mMMES, pH 6.5.
The upper panel shows the thermogram (thermal power as function of time) and the lower panel shows the
binding isotherm (normalized heat as a function of the molar ratio). The continuous line is the non-linear
fitting curve obtained using a model considering a single ligand binding site. The inset in the upper panel
shows a comparison of the thermodynamic binding profiles obtained by ITC for FMN interacting with
apoflavodoxins from S. pneumoniae, Helicobacter pylori, and Anabaena PCC7119:ΔG (black bars) ΔH
(gray bars) -TΔS (white bars). Data for theH. pylori and Anabaena complexes come from reference [28]
doi:10.1371/journal.pone.0161020.g005
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enthalpies (Table 2). As observed for other flavodoxins, FMN binding is markedly exothermic.
The overall binding process is enthalpically driven, with a small unfavorable entropic contribu-
tion. This suggests a considerable conformational entropy loss that is not compensated by the
desolvation entropy. A large part of the hydrophobic FMNmoiety (isoalloxazine ring) does
not become buried inside the binding site; moreover, the polar region of FMN strongly inter-
acts with amino acid residues in the active site and becomes completely buried upon binding.
The dissociation constant at 25°C is 83 nM, not far from that ofHelicobacter pylori flavodoxin
(27 nM), but two orders of magnitude higher than that of Anabaena flavodoxin (0.26 nM). As
previously observed for other flavodoxins, there is no significant exchange of protons coupled
to FMN binding (Table 2). The binding data obtained at the three temperatures indicated
allows estimating a binding heat capacity change of -0.5 kcal K-1mol-1, similar to that of other
flavodoxins.
X-ray structures of the apo and holo forms of SpFld
To understand the molecular basis of the interaction of the FMN cofactor with the protein
moiety and to provide a structural frame for the identification and characterization of SpFld
inhibitors, we have solved the crystal structures of the SpFld in the apo form (Fig 6a) and in
complex with FMN (Fig 6b and S1 Fig), at 2.18 and 1.69 Å, respectively (Table 3). Either struc-
ture shows the archetypical α/β sandwich flavodoxin fold (5 α-helices that pack against a five-
stranded β-sheet with a 21345 topology, forming an α/β/α sandwich). It has been reported that
some short-chain flavodoxins contain a bulge in the fifth beta strand that has been interpreted
as reminiscent of an evolutionary event where the long loop was lost from long-chain flavodox-
ins to give rise to short-chain flavodoxins [44]. This unique bulge is also found in the fifth beta
strand of Sp flavodoxin, unlike in any of the other four strands (Fig 7). Overall, the holo (note
that the holo form contains selenomethionine (SeMet) residues) and apo SpFld structures are
similar with an r.m.s.d of 0.8 Å. The main differences between the two structures are traced to
two of the three FMN binding loops encompassing residues 10–14 (phosphate loop), 57–66
(50’ loop) and 92–100 (90’ loop), the latter two sandwiching the isoalloxazinemoiety. A further
noticeable difference is the presence of a small 310 helix stretch at residues 38–40 in the holo-
protein that is absent in the apo form (Fig 6c).
Similar secondary structure induction due to FMN interaction is also observed in the crystal
structures of holo and apo forms of short-chain flavodoxinMioC of E. coli [47]. The extent of
the structural changes brought about by FMN binding in other flavodoxins of known structure
has been analysed using DaliLite [48]. The larger r.m.s.d. deviation between the holo and apo
Table 2. Apoflavodoxin/FMN binding energetics.
S. pneumoniaeb H. pyloria Anabaena PCC 7119a
Kd (nM) 83±9 27±6 0.26±0.06
ΔG (kcal mol-1) -9.7±0.1 -10.3±0.1 -13.1±0.1
ΔH0 (kcal mol-1) -11.6±0.3c -21.0±0.3 -11.2±0.2
-TΔS (kcal mol-1) 1.9±0.3 10.7±0.3 -1.9±0.2
ΔCp (kcal kmol-1) -0.5±0.1d -0.60±0.03 -0.60±0.02
nH 0.1±0.2c 0.1±0.2 0.1±0.2
a In 50 mMMOPS, pH 7.0 [28]
b In 100 mMMES, 150 mM NaCl, pH 6.5
c ΔH0 and nH were estimated by linear regression (see Methods).
d Estimated as the slope of ΔH vs T from experiments at 15, 20 and 25ÊC
doi:10.1371/journal.pone.0161020.t002
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Fig 6. Ribbon structure representation of apo SpFl in blue (a) and holo SpFld in cyan (b). Changes in the key FMN binding loops indicated in (b) can be
observed in the structural superimposition of the holo (cyan) and apo (blue) flavodoxins shown in (c). Also in (c), a red arrow points to a short 310 helix
formed in the holoprotein. The FMN-SpFld hydrogen bonding interactions are highlighted in (d).
doi:10.1371/journal.pone.0161020.g006
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forms was found for MioC Flavodoxin (2,6 Å), followed by Anabaena and Sp (0.8 Å), and then
H. pylori (0.5 Å). Those data show a high preservation of the backbone structure upon FMN
binding and indicate that segmental movements are essentially confined to the known dynamic
loops of the protein; 50´s-Loop and 90´s-Loop. Smaller changes are observed in the phosphate
binding loop upon FMN binding because, in the different apoproteins studied, this loop always
carries bound anions: a phosphate anion in Sp apoflavodoxin, a chloride anion inHelicobacter
pylori [26], or a sulfate anion in Anabaena [49] (S2 Fig).
Accommodation of the FMN into the Sp apoprotein takes place with changes in the dihedral
angles of several residues of the isoalloxazine binding loops. In the 57–66 loop, the main
changes are observed in residues G60, D61, G62 and E63, while in the 92–100 loop they occur
in residues D92, Y95 and D96. No significant changes are noticed in the FMN phosphate bind-
ing loop, possibly reflecting that the conformation adopted by this loop in the apoprotein is
highly influenced by the phosphate anion bound, which mimics the equivalent moiety in the
FMN of the holoprotein. In its bound conformation, the FMN phosphate group forms hydro-
gen bonds with S10 (sc), M11 (N), T12 (sc and N), N14 (N) and T15 (sc and N) (Fig 6d). As
previously reported for the apo/holo flavodoxin pairs in Anabaena PCC7119 andH. pylori
Table 3. Data collection and refinement statistics of holo and apo SpFld crystallographic structures.
SpFld-apo SpFld-FMN
(SeMet form)
Space group P212121 H3
Wavelength (Å) 0.92 0.976
Resolution (Å) 20±1.60 37.00±2.07
(1.69±1.60)a (2.18±2.07)
N. of molecules in Asymmetric unit 1 2
Cell dimensions (Å) a = 29.87 a = 101.68
b = 60.71 b = 101.68
c = 61.80 c = 68.28
Unique re¯ections 15310 15961
Completeness 99.2 (99.5) 99.2 (99.6)
Rsym 0.102 (0.703) 0.094 (0.421)
I/σ(I) 13.9 (2.7) 18.9 (6.7)
Mn(I) half-set correlation CC(1/2) 0.998 (0.810) 0.999 (0.934)
Redundancy 9.9 (9.6) 16.0 (16.1)
Alpha_twin 0.478
Rwork/Rfree 0.204/0.228 0.187/0.228
RMSD from ideal geometry, bonds (Å) 0.007 0.017
RMSD from ideal geometry, angles (Ê) 1.448 2.047
<B> overall (Å2) 15.32 39.22
<B> FMN (Å2) - 32.90
<B> solvent (Å2) 36.28 36.58
<B> phosphate (Å2) 11.97 -
Ramachandran plot:
Most favoured (%) 97.90 96.49
Additionally allowed (%) 2.10 3.51
Generously allowed (%)
a Values in parentheses refer to the highest resolution shell. Ramachandran plot statistics were determined
with PROCHECK, ref. [63].
doi:10.1371/journal.pone.0161020.t003
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[17, 26, 35, 49], the entrance of the FMN cofactor makes the two isoalloxazine binding loops to
move apart. In this reorganization, existing interactions between the two loops in the apoform
(Y95/G60 and E97/G62) are broken (Fig 8) and the protein expands: the holoprotein surface
area is 7745 Å compared to 7135 Å for the apoprotein (S3 Fig). In the holoprotein, FMN is
embedded by Y59, D92, E97, Y95, C99 and G60. The isoalloxazine ring of FMN establishes π-π
interactions with Y59 and Y95 (Fig 9). While the presence of a FMN binding tyrosine residue
is most common in the 90´s-Loop of flavodoxins, in the 50´s-Loop several other residues have
been reported (e.g.W, A, M or L).
Fig 7. Stick representation of the 5-stranded β-sheet of SpFld showing a characteristic bulge in strand 5, which has been
attributed [44] to originate in evolutionary splicing of two preexisting short strands, 5a and 5b that, in long-chain
flavodoxins, are connected by their characteristic long loop.
doi:10.1371/journal.pone.0161020.g007
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Interestingly, both Y59 and Y95 establish T-shape interactions with neighboringY57 and
F94, respectively (Fig 9). These aromatic pairs are not present in the apo form and it is possible
that they contribute to stabilize the conformation of the FMN-sandwiching residues. No such
aromatic pairs have been previously observed in the FMN binding sites of the other short-
chain flavodoxins of known structure (e.g.Desulfovibrio desulfuricans, D. vulgaris,D. gigas,
Clostridium Beijerinckii, Escherichia coli YqcA flavodoxin orMegasphaera elsdenii).
Fig 8. Stick representation of the FMN binding site in the Sp apo and holoflavodoxins indicating two key glycine residues (G60
and G62) that close the gap left by FMN in the apoprotein by interacting with residues of the 90' loop: Y95 and E97.
doi:10.1371/journal.pone.0161020.g008
Fig 9. Stick representation of the aromatic/aromatic pairs established by the FMN sandwiching Y59
and Y95 residues with neighboring Y57 and F94, respectively.
doi:10.1371/journal.pone.0161020.g009
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The flavodoxin fromDesulfovibrio vulgaris (Dv) is the short-chain flavodoxin for which
more detailed structural studies are available. Its sequence shows a 44% identity with that of Sp
flavodoxin. The structures of the two flavodoxins (Dv and Sp), superimposed in Fig 10, reveal
their high similarity (r.m.s.d. 1.2 Å), the main difference being noticed in the 50´s-Loop, which
is longer in Dv flavodoxin.While in the 90´s-Loop both flavodoxins use tyrosine residues with
Fig 10. Structural comparison of the short flavodoxins fromDesulfovibrio vulgaris (pdb id: 1j8q; ribbon and residues in green)
and from Streptococcus pneumoniae (this work, pdb id: 5lji; ribbon and residues in cyan). The FMN cofactors of the two
flavodoxins and the corresponding sandwiching aromatic residues (Y98 andW60 in Dv flavodoxin, and Y59 and Y95 in Sp flavodoxin) are
shown in a stick representation.
doi:10.1371/journal.pone.0161020.g010
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essentially identical orientations on the si face of FMN, in the 50´s-Loop the sandwiching aro-
matic residues in the two flavodoxins are different as are their orientations on the re face. The
interaction of the FMN phosphate at its binding loop is almost identical in the two flavodoxins,
as expected from the high conservation of this loop sequence. Finally, the hydrogen bonding
pattern of the polar atoms of the isoalloxazine rings (see Fig 6d for the Sp flavodoxin pattern) is
not identical in the two flavodoxins, but it is clearly analogous specially for the nitrogen atoms
(N3 and N10).
Suitability of SpFld as a novel drug target to combat Streptococcus
pneumoniae infections
Streptococcus pneumoniae infections cause more than one million deaths every year, affecting
principally young children and older people in developing countries. Appearance and propa-
gation of resistant strains, the relative ineffectiveness of some vaccines for some serotypes,
and virulence serotype changing, points towards an urgent search for novel Sp drug targets
[50]. Antibiotics being the main line of therapy to pneumococcal infections, the main issue in
pneumococcal infectionsmanagement is the rising frequency of antibiotic resistance, princi-
pally to penicillin,macrolides and also to fluoroquinolones [51]. In this context, the identifi-
cation of novel Sp-specific antibiotics is an important goal. Interestingly, a genome-wide
identification of essential genes in S. pneumoniae TIGR 4 strain in a murine meningitis model
identified three genes: adenylosuccinate synthetase (PurA), ABC transporter, and flavodoxin
[9]. Although the specific role of flavodoxin in S. pneumoniae has not been established, it is
clear that Sp infectiveness in this experimentalmeningitis model is severely attenuated in a
SpFld knockout mutant [9]. Taking as a precedent our own discovery of specific inhibitors of
the essential flavodoxin from the pathogenHelicobacter pylori, which are currently under pre-
clinical evaluation [31, 32], we propose that novel Sp-specific antimicrobials can be developed
based on inhibiting the activity of Sp flavodoxin. It is not obvious that theHp inhibitors previ-
ously discovered [31, 32] should be effective against Sp because SpFld lacks the pocket near
the FMN that is present inHp flavodoxin where an alanine residue replaces the usual aro-
matic residue at the 50´s-Loop. Therefore, to facilitate the development of Sp specific flavo-
doxin inhibitors, we have cloned, expressed Sp flavodoxin, and solved the x-ray structure of
both the apoprotein and the holo-form in complex with the FMN cofactor. Besides, we have
characterized its thermal stability, a convenient reporting property than can be used to iden-
tify potential inhibitors by detecting their stabilizing effects against thermal denaturation
exerted upon binding to the target protein. This work provides therefore the missing struc-
tural and thermodynamic knowledge of the Sp flavodoxin that will facilitate the search for
novel antimicrobials to inhibit SpFld function as a means to control the Streptococcus pneu-
moniae infection.
Materials and Methods
Cloning
The flavodoxin coding sequence was amplified from Streptococcus pneumoniae TIRGR4 geno-
mic DNA using the following primers:
5´-CGGAATTCGGATCCGGCAGCAGCCATCATCATCATCATCATCATCATGGCAGCGG
CCTGGAAGTTCTGTTCCAGGGGCCCATGGCATTAGCAAAAATTG-3´ and 5’-CGGAATTC
GTCGACTTAACCCACTTTCGCTGCCAGTTCTTC-3’,which additionally served to introduce
8 His residues at the N-terminal of the expressed protein. The resulting product from amplifi-
cation was digested and cloned into the pMALC2X using BamHI and SalI restriction sites
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(underlined). The plasmid was then introduced into DH5alpha E. coli cells (Life Technologies,
Inc., Rockville,MD, USA) and transformed cells were selected on Luria Bertani plates or in liq-
uid medium (LB) containing 100 µg ml-1 ampicillin (Sigma, St. Louis,MO, USA). Positive
clones identified by colony–PCR (BIORON) were sequenced and shown to contain the DNA
construct encoding the full length SpFld plus 8 additional histidine residues at theN-terminus.
Sp flavodoxin expression, purification and apoflavodoxin preparation
The BL21 (DE3) strain (Novagen), cultured in 2XTYmedia, was used for recombinant protein
overexpression. E. coli BL21 (DE3) cells were grown to an optical density of 0.6–0.8 at 37°C,
followed by induction with 1 mM IPTG (Sigma Aldrich). After 10 h of induction at 20°C, the
cells were collected by centrifugation at 11295 g for 20 min. The resulting pellet was suspended
in 160 ml of binding buffer (150 mMNaCl, 10 mM imidazole, 20 mM sodium phosphate
buffer, pH 7.4) per L of culture, and sonicated in ice in the presence of excess FMN, 5 µl of ben-
zonase (Sigma Aldrich, stock solution at 250 units µl-1) per 25 ml of solution, lysozyme (Sigma
Aldrich,>95% pure) final concentration 1 mg ml-1 and 500 µL protease inhibitors cocktail
stock solution (1 M PMSF + 10 mM benzamidine + 0.5 mM leupeptin) per 25 ml of cell vol-
ume, using 10 cycles, each consisting of a 30 s pulse plus a 30 s cooling step. The lysate was cen-
trifuged at 39086 g for 20 min. The cell pellet and its initial lysate showed a characteristic blue
color indicating the flavodoxin FMN cofactor was in the semiquinone redox state [2]. The
color changed to yellow (corresponding to oxidized FMN) as the purification progressed.
The supernatant was filtered through a 0.45 µmmembrane and loaded onto a Co2+HiTrap
TALON crude column (GE Healthcare) equilibrated with binding buffer. The column was
washed with binding buffer till negative Bradford reaction of the eluate, and the bound protein
was eluted using a 150 mMNaCl, 500 mM imidazole, sodium phosphate buffer, pH 7.4 (elu-
tion buffer). The eluted solution containing recombinant SpFld was dialyzed against 150 mM
NaCl, 25 mM Tris buffer pH 7.5 to remove the imidazole, and incubated overnight at 4°C with
0.5U of PreScission protease in order to remove the pMAL-(His)8 tail. The mixture was loaded
onto coupled GST and histidine columns (GE Healthcare) equilibrated in the dialysis buffer,
and SpFld without affinity tags was collected as the unbinding fraction, dialyzed against 25 mM
Tris pH 7.0, loaded into a 5 ml HiTrap Q FF column (GE Healthcare) equilibrated with 5 col-
umn volumes in the same buffer, and eluted with 5–10 column volumes with a linear NaCl gra-
dient from 0 to 1M in Tris 25 mM pH 7.0. Pure fractions according to SDS-PAGE were
concentrated to 2.5 ml by ultrafiltration using 10 kDa Centricons (Millipore) and loaded onto
a gel filtration column (Superdex 200 GE Healthcare) equilibrated with 150 mMNaCl, 25 mM
Tris, pH 7.5 from where a single peak corresponding to the monomer was collected. The purity
of the obtained SpFld was estimated to be>95% by SDS/PAGE (S4 Fig). A single band of 16
kDa was observed, in agreement with the expectedmolecularmass of 16025 Da. SpFld was dia-
lyzed against 150 mMNaCl, 100 mMMES pH 6.5, and concentrated to around 1 mM. Aliquots
were fast frozen in liquid nitrogen and stored at -80°C for further use.
For the crystallizationof FMN-bound flavodoxin, selenomethionine substituted SpFld was
similarly expressed in E. coli BL21 (DE3) strain, using the SelenoMethioninemedia fromMolec-
ular Dimensions. The protein was purified following the same protocol used for the native pro-
tein (see above). MALDI-TOFmass spectrometry, carried out in the Proteomics facility from
UAB, showed that three out of four possible selenomethionine residues were incorporated into
the protein. Sp apoflavodoxin (deprived from the FMN cofactor) was obtained by precipitation
with trichloroacetic acid (TCA) [52]. The protein pellet was washed five times with 3% w/v
TCA and 1 mMDTT, resuspended in 1 MMES pH 6.5, 15 mMNaCl, and subsequently dia-
lyzed in 150 mMNaCl, 100 mMMES, pH 6.5 and stored as the holoprotein.
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UV-Visible absorption, circular dichroism and fluorescence emission
spectra
The UV-visible absorption spectrumof holo and apo SpFld in 150 mMNaCl, 100 mMMES,
pH 6.5, was collected at 25°C using a Cary 100Biospectrometer (Varian). To estimate SpFld
apoflavodoxinmolar extinction coefficient in 150 mMNaCl, 100 mMMES, pH 6.5 (working
buffer), the Gill von Hippel method was used [37]. The extinction coefficient of the denatured
protein in 6 M guanidine-HCl, 20 mM phosphate sodium, pH 6.5, was first calculated from its
content of cysteines and tyrosines. Then, the ratio of absorbances at the wavelength selected of
protein solutions or equal concentration prepared in either denaturing buffer or in working
buffer equaled the ratio of the calculated extinction coefficients in denaturing buffer over that
in working buffer. All measures were done by triplicate. To determine the holoflavodoxin
extinction coefficient, the Mayhew and Massey method was used [38].
Far-UV, near-UV and visible-UV circular dichroism (CD) spectra of the holo and apopro-
teins in 150 mMNaCl, 100 mMMES, pH 6.5, were acquired at 4°C in a Chirascan spectropo-
larimeter (Applied-Photophysics). For near-UV and visible spectra, 80 µM protein solutions in
a 1-cm path-length cuvette were used, while for far-UV, 80 µM protein solutions were used in a
0.01-cm path-length cuvette. To accurately determine the concentration of protein in the CD
samples, small volumes of concentrated stock solutions of either apo or holoflavodoxin were ini-
tially diluted to prepare solutions that provided an approximation to the actual concentrations.
Based on that, protein samples around 80 µMwere prepared and used to acquire the CD spec-
tra. After having recorded the CD spectra, the actual concentrations of those samples were accu-
rately determined by recording their full absorbance spectra. For apoflavodoxin quantification
the near-UV peak was used, and for holoflavodoxin quantification the major visible peak was
used. The absorbances of either of those peaks were of around 0.7 in a 1 cm path-length cuvette
and allowed a fine determination of protein concentration using the corresponding extinction
coefficients.These concentrations were finally used for the MRE calculation leading to Fig 2a.
Fluorescence emission spectra of 20 µM holoprotein or apoprotein, in 150 mMNaCl, 100 mM
MES, pH 6.5, were recorded at 10°C from 275 to 750 nm or from 290 to 500 nm, respectively,
with excitation at 270 nm, using a Cary Eclipse spectrofluorometer (Varian).
Thermal denaturation followed by spectroscopy
Holo and apo SpFld thermal denaturation was followed, from 8 to 90°C, by CD. Unfolding
curves for the holoprotein were acquired at 220 nm (far-UV CD) and at 272 nm (near-UV
CD) with heating rates of 1°Cmin-1. For the apoprotein, the wavelengths used were 221 and
285 nm, respectively. For near-UV, a 1-cm path-length quartz cuvette was used and the sam-
ples were prepared with the same buffer and protein concentration used for recording the CD
spectra, while for far-UV CD a 0.1-cm path-length cuvette and 80 µM protein solutions were
used. The thermal denaturation of the holoprotein was followed, from 8 to 80°C, by fluores-
cence in the visible region (excitation and emission of 464 and 525 nm, respectively) associated
to FMN release coupled to protein unfolding, using a heating rate of 1°Cmin-1. Protein con-
centration and buffer conditions were those used for acquiring the fluorescence spectrum
(20 µM for both, holo- and apoprotein). Each individual curvewas fitted to a two-state model,
as previously described [53, 54], using the following equations:
S ¼
SN þ mN  T þ ðSU þ mU  TÞ  e
  DG=RT
1þ e  DG=RT
ð1Þ
DGðTÞ ¼ DHm  ð1   ðT=TmÞÞ   DCP;m  ððTm   TÞ þ T lnðT=TmÞÞ ð2Þ
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where “S” is the observed spectroscopic signal at a given temperature, and “SN(U) + mN(U) × T”
represents the temperature-dependent intrinsic signal of either the native (N subscript) or the
unfolded (U subscript) protein, R is the ideal gas constant, T is the absolute temperature, and
ΔG is the unfolding Gibbs energy change, which can be expressed in terms of the mid-transi-
tion temperature Tm, the unfolding enthalpy change ΔHm, and the unfolding heat capacity
change ΔCP,m. Because all the individual thermal unfolding curves of either the apo- or the
holoprotein acquired following different spectroscopic signals could be superimposed, each
group of curves (from either holo or apoflavodoxin) was also globally fitted to the two-state
unfoldingmodel, as described [53, 54].
Thermal denaturation followed by differential scanning calorimetry
Differential scanning calorimetry (DSC) assays were performed on 40 µM apo SpFld in the
absence or presence of FMN (40 and 1000 µM). Measurements (from 10 to 100°C at a scanning
rate of 1°Cmin-1) were performed in a VP-DSC microcalorimeter (MicroCal LLC, Northamp-
ton, MA), and rescans were recorded after cooling to 10°C. The reference and sample solutions
were degassed and carefully loaded into the cells to avoid bubble formation. Baselines were
recorded before each assay with the reference and sample cells filledwith buffer (150 mM
NaCl, 100 mMMES, pH 6.5). Data analysis, using the software package ORIGIN (OriginLab),
was based on the model-free van´t Hoff analysis. Briefly, from the thermal unfolding assay the
mid-transition temperature Tm and the calorimetric enthalpy ΔHcal could be determined and,
from those values, the van’t Hoff enthalpy was estimated as:
DHvH ¼
4RT2mhDCP;trimax
DHcal
ð3Þ
where<ΔCP,tr>max is the maximal value of the excess molar heat capacity of the protein [55].
The van’t Hoff enthalpy is equivalent to the unfolding enthalpy obtained from analysis of spec-
troscopic techniques, and: a) it is equal to the calorimetric enthalpy if the thermal unfolding
follows a two-state mechanism; b) it is smaller than the calorimetric enthalpy if the thermal
unfolding follows a non-two-state mechanism with partially folded intermediates; and c) it is
higher than the calorimetric enthalpy if the thermal unfolding follows a two-state mechanism
where the native protein self-associates in oligomers [56]. Once the appropriate unfolding
model has been determined, the unfolding curve can be analyzed accordingly.
FMN binding by isothermal titration calorimetry
Isothermal titration calorimetry (ITC) measurements were carried out in a MicroCal Auto-
iTC200 (MicroCal/GEHealthcare) using carefully degassed cofactor and protein solutions. A
300 µM solution of FMN (Sigma-Aldrich,>95% pure) dissolved in 150 mMNaCl, 100 mM
MES, pH 6.5 was titrated into 20 µM apo SpFld, in the same buffer. Intervals of 700 s between
injections were allowed to guarantee recovery of the base line. Data were analyzed with a one-
site bindingmodel implemented in the Origin (OriginLab) software package. Binding titrations
were performed at 15, 20 and 25°C to obtain the binding heat capacity as the temperature
derivative of the observedbinding enthalpy. Additional assays required for assessing proton
exchange processes coupled to ligand binding were performed in 150 mMNaCl 50 mMMOPS
pH 6.5 at 25°C. The buffer-independent binding enthalpy ΔH0, and the net number of protons
exchanged nH were estimated by performing assays using buffers with different ionization
enthalpies and linear regression using eq 4:
DHobs ¼ DH0 þ nHDHion ð4Þ
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where ΔHobs is the enthalpy obtained in a given assay and ΔHion is the ionization enthalpy of
the buffer.
Dithionite titration of SpFld holoflavodoxin
To observe the spectra of the different redox states of SpFld, a sodium dithionite reduction was
performed at 10°C using 20 µM protein in 150 mMNaCl, 100mMMES buffer, pH 6.5 under
pseudo-anaerobic conditions. A concentrated anaerobic sodium dithionite solution (50 mM)
was prepared in the same buffer by sequential evacuation and re-equilibration with oxygen-
free argon. Pseudo-anaerobic conditions were achieved in the spectrophotometer cell by argon
flux. Stepwise SpFld reductionwas achieved by addition of 2.5–10ml aliquots of sodiumdithio-
nite to the protein sample. After each addition, the UV-Vis spectrumwas recorded in a Cary
100 spectrophotometer (Varian).
Crystallization and data collection
Crystallization trials were carried out using the sitting-drop vapor diffusionmethod at 18°C.
The drops were prepared by mixing 0.5 µL of protein solution containing either holo (62 mg
ml-1) or apoprotein (127 mg ml-1) in 100 mMMES, 150 NaCl, pH 6,5 buffer with 0.5 µL of the
mother liquor. Crystals of the holoprotein (though these crystals contain selenomethionine,
they are referred here as our holo form) were grown in 45% 2-Methyl-2,4-pentanediol (MPD),
100 mM Bis-Tris pH 5.5 and 200 mM calcium chloride, apoprotein form crystals were
obtained in 10% glycerol and 2 M ammonium sulphate. Crystals were formed after 3–8 days.
Best apoprotein and holoprotein SpFld crystals were immersed, respectively, in the same reser-
voir solution or in the same solution with 20% of glycerol for cryoprotection.All diffraction
datasets were collected at the Diamond synchrotron light source (DLS).
Structure determination, phase calculation, model building and
refinement
Initial molecular replacement trials were attempted using MOLREP [57] with the data from a
holo crystal processed as H3 (note that the holo form contains SeMet residues) and the struc-
ture of Desulfovibrio desulfuricans flavodoxin (PDB code: 3F9O) as search model; however, no
improvement in Rfactor and Rfree was observedduring refinement. The program SOLVE [58]
was used for initial phasing by single anomalous dispersion (SAD). Despite the data collection
had been performed using a suboptimal wavelength (λ = 0.976Å), the positions of the 3 Se
atoms were determined. Subsequent phasing and solvent flattening were carried out using
SOLVE and RESOLVE [59] as implemented in PHENIX [60]. A solvent flattened Se-SAD
derived electron density map was used for automatic construction of the holo SpFld structure
with RESOLVE. The automatic building process resulted in a model formed by 76 residues in
11 chains. Remarkably, one of the chains was an alpha helix that appeared at the same position
in the previousMR attempt. Then, we built a more complete model with the program PHE-
NIXAutoBuild and using the initial MR solution as initial model in combination with the Se-
SAD density map obtained previously. The resulting model contained 143 residues positioned
in 2 chains, with Rfact and Rfree of 0.29 and 0.36 respectively. We completed the model manu-
ally with Coot [61] and refined with REFMAC [62], obtaining Rfact and Rfree values of 0.25 and
0.33 respectively. Finally, the combination of adding FMN, water molecules and new rounds of
model building in Coot and TLS restrained refinement in REFMAC, rendered Rfact and Rfree
values of 0.187 and 0.228, respectively.
To solve the structure of the SpFld apoprotein, molecular replacement was performed using
MOLREP[58] with the holoprotein SpFld structure as startingmodel and the data in the space
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group P212121. Iterative rounds of manual building in Coot and TLS restrained refinement in
REFMAC were also performed, and the final model was validated with PROCHEK [63]. All
figures were generated with PyMoL (http://wwwrcsb.org). Coordinates and structure factors
have been deposited in the protein data bank under accession code 5LJI and 5LJL for the holo
and apo form, respectively.
Supporting Information
S1 Fig. Electrondensity map is FO − FC syntheses (blue) contoured at 2.2 s for FMN.
(PNG)
S2 Fig. Superimposition of apo SpFld (blue) and sulfate anion (magenta-red)with apo fla-
vodoxin structures of E. coliMioC (pale blue) (a),Helicobacter pylori (yellow) and chloride
anion (green) (b),Anabaena (salmon) and sulfate ion (c).
(TIF)
S3 Fig. Surface representation of apo (a) and holo form (b) of SpFld. Protein is coloured in
grey whereas FMN carbon atoms are coloured in white.Note that FMN induces the forma-
tion of a larger pocket in the holo form (in which FMN locates) in comparison with a smaller
pocket present in the apo structure.
(TIF)
S4 Fig. SpFld size and purity analyses by 12% SDS-PAGE; line 1: molecularmassmarkers,
line 2: SpFld at the end purification process.
(TIF)
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